| 5-FU | 5-fluorouracil |
| APC | Antigen presenting cell |
| APM | Antigen presenting machinery |
| B2M | β 2 microglobulin |
| BMMR-D | Biallelic mismatch repair deficiency syndrome |
| CCL | Chemokine (cc motif) ligand |
| cGAMP | Cyclic guanosine monophosphate-adenosine monophosphate |
| c-GAS | Cyclic GMP-AMP synthase |
| CIMP | CpG island methylator phenotype |
| CMS | Consensus molecular subtype |
| CN-LOH | Copy-neutral loss of heterozygosity |
| CPIs | Checkpoint inhibitors |
| CRC | Colorectal cancer |
| CSF1-R | Colony stimulating factor 1 receptor |
| CTLA4 | Cytotoxic T-lymphocyte antigen 4 |
| CTNNB1 | β -catenin |
| CXC | Chemokine (cxc motif) |
| CXCL | Chemokine (cxc motif) ligand |
| DBS | Double base substitution |
| DC | Dendritic cell |
| DCR | Disease control rate |
| DFCI | Dana Farber Cancer Institute |
| DOR | Duration of response |
| ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 |
| ERP57 | Endoplasmic reticulum protein 57 |
| EXO 1 | Exonuclease 1 |
| FOXP 3 | Forkhead box 3 |
| FS | Frameshift |
| GATA3 | GATA binding protein 3 |
| GROα | Growth regulated protein α |
| GSK3B | Glycogen synthase kinase 3 beta |
| HLA | Human leukocyte antigen |
| HNPCC | Hereditary non-polyposis colorectal cancer |
| HPV | Human Papilloma Virus |
| ICOS | Inducible T-cell costimulator |
| IDO | Indoleamine 2,3-dioxygenase |
| IL- | Interleukin- |
| IL1RA | IL-1 receptor agonist |
| IN/DEL | Insertion/deletion |
| INF | Interferon |
| IRF3 | Interferon regulatory factor 3 |
| JAK | Janus kinases |
| LAG3 | Lymphocyte activation gene 3 |
| M1 | M1-like macrophages |
| M2 | M2-like macrophages |
| mCRC | Metastatic CRC |
| MDSC | Myeloid derived suppressor cells |
| MGMT | O6-methylguanine-DNA methyltransferase |
| MHC | Major histocompatibility complex |
| MLH1 | MutL homolog 1 |
| MMR | Mismatch repair |
| MMRd | Mismatch repair deficient |
| MMRp | Mismatch repair proficient |
| mPFS | Median progression free survival |
| MSH2 | MutS homolog 2 |
| MSH6 | MutS homolog 6 |
| MSI | Microsatellite instability |
| MSS | Microsatellite stable |
| NFKB | Nuclear factor Kappa-ligand-chain-enhancer of activated B cells |
| NGS | Next generation sequencing |
| NK | Natural killer |
| NKG2D | Natural killer group 2 member D |
| NLRC5 | NLR family CARD domain containing 5 |
| NSCLC | Non-small cell lung cancer |
| ORR | Objective response rate |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed cell death protein ligand 1 |
| PFS | Progression free survival |
| PMS2 | PMS1 homolog 2 |
| POLD1 | Polymerase delta 1 |
| POLE | Polymerase epsilon |
| RAE1 | Retinoic acid early transcript 1 ligand |
| RCC | Renal cell carcinoma |
| RFX5 | Regulatory factor X5 |
| ROS | Reactive oxygen species |
| RPA | Replication protein A |
| SBS | Single base substitution |
| SNVs | Single nucleotide variants |
| STAT | Signal transducer and activator of transcription |
| STING | Stimulator of interferon gene |
| TAM | Tumor associated macrophages |
| TAP | Transporter associated with antigen processing |
| TCF4 | T cell factor 4 |
| TCGA | The Cancer Genome Atlas |
| TCR | T cell receptor |
| Tfh | T follicular helper |
| TGFBR2 | TGF-β receptor 2 |
| TGF-β | Transforming growth factor β |
| Th1 | T-helper type 1 |
| TIM3 | T-cell immunoglobulin and mucin domain-3 |
| TMB | Tumor mutational burden |
| Treg | Regulatory T cells |
| VEGF | Vascular endothelial growth factor |
| VISTA | V-domain Ig suppressor of T cell activation |